Metabolic Health
Semaglutide for Weight Loss: Who Actually Benefits — and Who Should Skip It
Semaglutide has redefined what's possible in weight management, delivering average body weight reductions of 15% in landmark trials — results previously seen only with bariatric surgery. But the drug comes with real contraindications, a steep discontinuation rebound risk, and a growing list of compounded alternatives flooding the market. Here's what the evidence actually says about who should use it, who shouldn't, and what else belongs in a comprehensive metabolic strategy.

What Is Semaglutide and How Does It Promote Weight Loss?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed to manage type 2 diabetes (marketed as Ozempic at lower doses) and later approved by the FDA specifically for chronic weight management under the brand name Wegovy at a 2.4 mg weekly subcutaneous dose. It works by mimicking endogenous GLP-1, a gut hormone released after meals that slows gastric emptying, suppresses appetite signaling in the hypothalamus, and reduces glucagon secretion — a combination that dramatically lowers caloric intake without requiring conscious effort.
The STEP 1 trial, the pivotal phase 3 study that led to Wegovy's approval, enrolled 1,961 adults with a BMI ≥30 (or ≥27 with a weight-related comorbidity) and found that participants receiving 2.4 mg semaglutide weekly lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% in the placebo group (Wilding et al., New England Journal of Medicine 2021; PMID: 33567185). That magnitude of loss was unprecedented for a pharmacological agent in a randomized controlled trial.
Beyond the scale, semaglutide also improved waist circumference, blood pressure, fasting glucose, and triglyceride levels — markers that directly connect excess weight to cardiovascular and metabolic disease risk. Understanding why borderline cholesterol numbers matter is part of framing why these secondary metabolic improvements are clinically significant.
---
Who Actually Benefits Most from Semaglutide for Weight Loss
Not everyone loses the same amount of weight on semaglutide, and clinical profiles predict outcomes better than enthusiasm does. The people who tend to benefit most include:
- Adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or type 2 diabetes) — this is the FDA-approved indication
- People with insulin resistance or prediabetes, in whom GLP-1 signaling is often blunted, making pharmacologic amplification particularly impactful
- Individuals who have failed repeated lifestyle interventions — semaglutide's appetite suppression overcomes the compensatory hunger hormones (particularly ghrelin) that make caloric restriction so difficult to sustain
- Those with established cardiovascular risk — the SELECT trial (2023) showed semaglutide reduced major adverse cardiovascular events by 20% in non-diabetic overweight adults with prior cardiovascular disease (Lincoff et al., NEJM 2023; PMID: 37952131)
- Patients with non-alcoholic fatty liver disease (NAFLD), where the drug's hepatic effects on fat metabolism add a secondary benefit beyond weight loss alone
If you're tracking ApoB or LDL as cardiovascular risk markers, it's also worth reading about what supplements can affect ApoB levels alongside any pharmaceutical approach.
---
Who Should Skip Semaglutide (or Approach It with Caution)
Despite its remarkable efficacy, semaglutide is contraindicated or carries meaningful risk for several groups:
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2) — GLP-1 receptors are expressed on thyroid C cells, and rodent studies showed dose-dependent thyroid tumors (the clinical relevance in humans remains under investigation, but the FDA black-box warning stands)
- History of pancreatitis — GLP-1 agonists increase pancreatic enzyme activity; individuals with prior acute or chronic pancreatitis should avoid this class
- Pregnancy or breastfeeding — weight loss medications are contraindicated during pregnancy due to fetal nutrition requirements
- Severe gastrointestinal conditions (gastroparesis, inflammatory bowel disease) — semaglutide further slows gastric emptying, which can worsen these conditions significantly
- Type 1 diabetes — this is an off-label use with insufficient safety data
- People seeking a short-term fix — perhaps the most underappreciated contraindication is behavioral. The STEP 4 withdrawal trial demonstrated that participants who stopped semaglutide regained approximately two-thirds of their lost weight within one year (Rubino et al., JAMA 2021; PMID: 34078801). Without addressing the underlying metabolic and behavioral drivers, discontinuation typically results in full weight restoration.
| Factor | Likely Benefit | Use Caution / Avoid |
|---|---|---|
| BMI ≥30 or ≥27 + comorbidity | ✓ | — |
| Cardiovascular disease history | ✓ | — |
| Insulin resistance / prediabetes | ✓ | — |
| Personal/family history MTC or MEN2 | — | ✗ Contraindicated |
| Prior pancreatitis | — | ✗ Avoid |
| Pregnancy / breastfeeding | — | ✗ Contraindicated |
| Gastroparesis | — | ✗ Avoid |
| Goal: short-term quick fix only | — | ⚠️ High rebound risk |
---
Compounded Semaglutide for Weight Loss: What You Need to Know
During the 2022–2024 FDA drug shortage of Wegovy and Ozempic, compounding pharmacies legally filled a gap by producing compounded semaglutide. As of 2025, the FDA has resolved the shortage designations for both drugs and has stated that compounded versions using semaglutide base are no longer permissible under the shortage exemption — though tirzepatide compounding remains a separate regulatory conversation.
If you are currently using or considering compounded semaglutide for weight loss, several quality concerns warrant attention:
- Purity and potency verification — unlike FDA-approved Wegovy, compounded versions are not subject to the same manufacturing controls. Independent lab analyses have identified significant variability in dose accuracy.
- Salt vs. free-base formulations — some compounds use semaglutide sodium or acetate salts rather than the active free base. The bioequivalence of these forms has not been established in peer-reviewed human trials.
- Additives — compounded products sometimes include add-ons like B12 or L-carnitine; the clinical justification for these combinations is thin.
- Regulatory standing — the FDA issued warning letters to multiple compounders in 2024 for misbranding. Confirm current legal status with a licensed prescriber before sourcing.
For individuals who cannot access brand-name semaglutide due to cost or supply, working with a physician at a licensed 503B outsourcing facility represents the most defensible path.
---
Ginger for Weight Loss: Modest but Real Supporting Evidence
While semaglutide dominates the pharmacological conversation, many people using GLP-1 medications also experience significant nausea — the drug's most common side effect, reported in up to 44% of STEP trial participants. This is where ginger (Zingiber officinale) has genuine clinical relevance as a complementary tool.
A 2019 systematic review and meta-analysis in Critical Reviews in Food Science and Nutrition analyzed 14 randomized controlled trials and found that ginger supplementation produced statistically significant reductions in body weight, waist-to-hip ratio, and fasting glucose compared to placebo (Maharlouei et al., Critical Reviews in Food Science and Nutrition 2019; PMID: 30545184). Effect sizes were modest — typically 0.5–1.5 kg of additional weight loss over 8–12 weeks — but meaningful as an adjunct.
The mechanisms relevant to metabolic health include:
- Gingerols and shogaols activating AMPK, an energy-sensing enzyme that promotes fat oxidation
- Inhibition of intestinal lipase, reducing dietary fat absorption
- Anti-inflammatory effects in adipose tissue that may reduce metabolic dysfunction
For semaglutide users specifically, ginger's well-validated antiemetic properties — documented in oncology and obstetric literature — may help manage the nausea that leads many patients to discontinue therapy before reaching therapeutic dose.
---
Boswellia for Weight Loss: Anti-Inflammatory Mechanisms Worth Understanding
Boswellia serrata (Indian frankincense) is primarily discussed in the context of joint health and inflammation, but its relevance to metabolic health is growing. Chronic low-grade adipose tissue inflammation is now understood as a driver of insulin resistance and impaired weight loss — not just a consequence of obesity. Adipose macrophage infiltration, elevated TNF-α, and IL-6 signaling create a metabolic environment where losing weight becomes progressively harder.
Boswellic acids — particularly AKBA (acetyl-11-keto-β-boswellic acid) — inhibit 5-lipoxygenase (5-LOX), reducing leukotriene synthesis and thereby attenuating this inflammatory cascade. While direct boswellia for weight loss RCTs in humans remain limited, the mechanistic rationale is scientifically sound. One 2015 trial found that a standardized Boswellia extract significantly reduced inflammatory markers (CRP, IL-6) in overweight adults (Sengupta et al., International Journal of Medical Sciences 2010; PMID: 20671814), which supports its role in creating a more favorable metabolic baseline.
If you're managing cholesterol alongside weight, the anti-inflammatory properties of compounds like boswellia are worth pairing with a broader lipid strategy — including understanding how long it takes to lower total cholesterol through diet and supplementation.
---
Glucosamine for Weight Loss: Separating Signal from Noise
Searches for glucosamine for weight loss tend to come from people who've heard that this joint supplement has unexpected metabolic effects — and that intuition isn't entirely wrong, though the evidence is preliminary. Glucosamine is an amino monosaccharide involved in cartilage synthesis, but it also activates the hexosamine biosynthetic pathway (HBP), which plays a role in cellular energy sensing.
Observational data from large epidemiological studies have noted that regular glucosamine users tend to have lower rates of cardiovascular disease mortality and, in some analyses, slightly lower BMI. However, this is classic confounding territory — people who take glucosamine tend to also exercise more and have more health-aware behaviors. No rigorous RCT has demonstrated that glucosamine causes meaningful weight loss in humans.
For most people considering glucosamine, joint health and cartilage support remain its evidence-backed indication. Reframing it as a weight loss supplement based on epidemiological signals would overstate what the science currently supports. If you are specifically looking for supplements with demonstrated impact on metabolic markers, omega-3 fatty acids for cardiovascular and metabolic health have a substantially stronger evidence base.
---
What This Means for Your Formula
Semaglutide is a pharmaceutical intervention, not a supplement — Ones doesn't prescribe medications, and nothing in a personalized supplement formula replaces a GLP-1 agonist if one is clinically indicated. What Ones does address is the broader metabolic and inflammatory context that determines how well any weight management strategy works.
For individuals on semaglutide or pursuing weight loss through lifestyle means, Ones' AI health practitioner analyzes blood work and health data to identify gaps that blunt metabolic progress:
- Omega-3 (EPA/DHA): Ones includes clinically dosed EPA and DHA to address the chronic adipose inflammation that underlies insulin resistance. The AHA recognizes EPA+DHA at 2–4 g/day for elevated triglycerides, and Ones calibrates dose to your lipid panel rather than using a one-size number.
- Liver Support (System Blend): For individuals with NAFLD or elevated liver enzymes — common in metabolic syndrome — Ones' proprietary Liver Support blend includes hepatoprotective ingredients relevant to fat metabolism. Given that semaglutide itself benefits NAFLD patients, supporting hepatic function through supplementation is a logical complement.
- Magnesium Complex: Magnesium deficiency is highly prevalent in overweight individuals and directly impairs insulin signaling. Ones' Magnesium Complex uses highly bioavailable forms dosed based on your specific intake gaps, not a generic RDA estimate.
If your weight loss has stalled despite medication or lifestyle changes, a personalized review of your blood markers — including fasting insulin, ApoB, and inflammatory markers like CRP — often reveals the correctable gaps that make the difference. You can also explore how diet changes affect ApoB to understand which nutritional levers move the needle most.
---
Key Takeaways
- Semaglutide produces clinically significant weight loss (averaging ~15% body weight in STEP 1) in adults with obesity or overweight plus metabolic comorbidities — but requires lifelong use to sustain results, since most weight is regained after discontinuation.
- Contraindications are real and important: personal or family history of MTC or MEN2, prior pancreatitis, pregnancy, and gastroparesis are primary reasons to avoid this drug class.
- Compounded semaglutide occupies a legally and qualitatively uncertain space in 2025 — work with a licensed prescriber and verify pharmacy credentials before sourcing it.
- Ginger provides meaningful antiemetic and modest metabolic support — particularly relevant for managing the nausea that causes early discontinuation of GLP-1 therapy.
- Boswellia's anti-inflammatory properties address the adipose inflammation that impairs metabolic function, though it should not be positioned as a primary weight loss agent.
- Glucosamine's association with metabolic health in epidemiological data is interesting but confounded — its primary clinical role remains joint support, not weight loss.
- A comprehensive metabolic strategy addresses the inflammatory, hepatic, and nutritional context around weight management — which is where precision supplementation, informed by your actual lab data, adds real value.